Systemic endemic mycoses cause high rates of morbidity and mortality in certain regions of the world and the real impact on global health is not well understood. Diagnosis and management remain challenging, especially in low-prevalence settings, where disease awareness is lacking. The main challenges include the variability of clinical presentation, the fastidious and slow-growing nature of the fungal pathogens, the paucity of diagnostic tests, and the lack of options and toxicity of antifungal drugs. Coccidioidomycosis and paracoccidioidomycosis are restricted to the Americas only, and while histoplasmosis and blastomycosis also occur predominantly in the Americas, these mycoses have also been reported on other continents, especially in sub-Saharan Africa. Talaromycosis is endemic in tropical and subtropical regions in South-East Asia and southern China. Systemic endemic mycoses causing pulmonary disease are usually acquired via the airborne route by inhalation of fungal spores. Infections can range from asymptomatic or mild with flu-like illnesses to severe pulmonary or disseminated diseases. Skin involvement is frequent in patients with paracoccidioidomycosis, blastomycosis, sporotrichosis, and talaromycosis and manifests as localized lesions or diffuse nodules in disseminated disease, but can also occur with other endemic mycoses. Culture and/or characteristic histopathology from clinical samples is the diagnostic standard for endemic mycoses. Immunological assays are often not available for the diagnosis of most endemic mycoses and molecular amplification methods for the detection of fungal nucleic acids are not standardized at present. The first-line treatment for mild to moderate histoplasmosis, paracoccidioidomycosis, blastomycosis, sporotrichosis, and talaromycosis is itraconazole. Severe illness is treated with amphotericin B. Patients with severe coccidioidomycosis should receive fluconazole. Treatment duration depends on the specific endemic mycosis, the severity of disease, and the immune status of the patient, ranging between 6 weeks and lifelong treatment.

Journal Section:
Editor's choice
Keywords:
Endemic mycoses, Pulmonary disease, Diagnosis, Management, Treatment
1.
Mirsaeidi M, Motahari H, Taghizadeh Khamesi M, Sharifi A, Campos M, Schraufnagel DE: Climate change and respiratory infections. Ann Am Thorac Soc 2016; 13: 1223–1230.
2.
Wheat LJ, Conces D, Allen SD, Blue-Hnidy D, Loyd J: Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med 2004; 25: 129–144.
3.
Benedict K, Derado G, Mody RK: Histoplasmosis-associated hospitalizations in the United States, 2001–2012. Open Forum Infect Dis 2016; 3:ofv219.
4.
Capone D, Wanke B, Monteiro PC, Lazera MS, de Noronha Andrade G, do Valle AC, Moreno AM, Londero AT: Chronic pulmonary histoplasmosis in the state of Rio de Janeiro, Brazil. Mycopathologia 1999; 145: 75–79.
5.
Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ: Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50: 85–92.
6.
Zerbe CS, Holland SM: Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis 2005; 41:e38–e41.
7.
Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL; Infectious Diseases Society of America: Coccidioidomycosis. Clin Infect Dis 2005; 41: 1217–1223.
8.
Nicas M: A point-source outbreak of Coccidioidomycosis among a highway construction crew. J Occup Environ Hyg 2018; 15: 57–62.
9.
Crum N, Lamb C, Utz G, Amundson D, Wallace M: Coccidioidomycosis outbreak among united states navy seals training in a Coccidioides immitis-endemic area – Coalinga, California. J Infect Dis 2002; 186: 865–868.
10.
Petersen LR, Marshall SL, Barton-Dickson C, Hajjeh RA, Lindsley MD, Warnock DW, Panackal AA, Shaffer JB, Haddad MB, Fisher FS, Dennis DT, Morgan J: Coccidioidomycosis among workers at an archeological site, northeastern Utah. Emerg Infect Dis 2004; 10: 637–642.
11.
Williams PL, Sable DL, Mendez P, Smyth LT: Symptomatic coccidioidomycosis following a severe natural dust storm. An outbreak at the Naval Air Station, Lemoore, Calif. Chest 1979; 76: 566–570.
12.
Osaki T, Morishita H, Maeda H, Kamei K, Hoshino S, Kijima T, Kumagai T, Yoshida M, Tachibana I, Kawase I: Pulmonary coccidioidomycosis that formed a fungus ball with 8-years duration. Intern Med 2005; 44: 141–144.
13.
Capone D, Marchiori E, Wanke B, Dantas KE, Cavalcanti MA, Deus Filho A, Escuissato DL, Warszawiak D: Acute pulmonary coccidioidomycosis: CT findings from 15 patients. Br J Radiol 2008; 81: 721–724.
14.
Shikanai-Yasuda MA, Mendes RP, Colombo AL, Queiroz-Telles F, Kono ASG, Paniago AM, Nathan A, Valle A, Bagagli E, Benard G, Ferreira MS, Teixeira MM, Silva-Vergara ML, Pereira RM, Cavalcante RS, Hahn R, Durlacher RR, Khoury Z, Camargo ZP, Moretti ML, Martinez R: Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop 2017; 50: 715–740.
15.
Bethlem EP, Capone D, Maranhao B, Carvalho CR, Wanke B: Paracoccidioidomycosis. Curr Opin Pulm Med 1999; 5: 319–325.
16.
Barrozo LV, Benard G, Silva ME, Bagagli E, Marques SA, Mendes RP: First description of a cluster of acute/subacute paracoccidioidomycosis cases and its association with a climatic anomaly. PLoS Negl Trop Dis 2010; 4:e643.
17.
do Valle ACF, Marques de Macedo P, Almeida-Paes R, Romao AR, Lazera MDS, Wanke B: Paracoccidioidomycosis after highway construction, Rio de Janeiro, Brazil. Emerg Infect Dis 2017; 23: 1917–1919.
18.
Panackal AA, Hajjeh RA, Cetron MS, Warnock DW: Fungal infections among returning travelers. Clin Infect Dis 2002; 35: 1088–1095.
19.
McTaggart LR, Brown EM, Richardson SE: Phylogeographic analysis of Blastomyces dermatitidis and Blastomyces gilchristii reveals an association with North American freshwater drainage basins. PLoS One 2016; 11:e0159396.
20.
Roy M, Benedict K, Deak E, Kirby MA, Mc­Niel JT, Sickler CJ, Eckardt E, Marx RK, Heffernan RT, Meece JK, Klein BS, Archer JR, Theurer J, Davis JP, Park BJ: A large community outbreak of blastomycosis in Wisconsin with geographic and ethnic clustering. Clin Infect Dis 2013; 57: 655–662.
21.
Azar MM, Assi R, Relich RF, Schmitt BH, Norris S, Wheat LJ, Hage CA: Blastomycosis in Indiana: clinical and epidemiologic patterns of disease gleaned from a multicenter retrospective study. Chest 2015; 148: 1276–1284.
22.
Kauffman CA, Bustamante B, Chapman SW, Pappas PG; Infectious Diseases Society of America: Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 1255–1265.
23.
Kauffman CA: Sporotrichosis. Clin Infect Dis 1999; 29: 231–236; quiz 237.
24.
Sanchotene KO, Madrid IM, Klafke GB, Bergamashi M, Della Terra PP, Rodrigues AM, de Camargo ZP, Xavier MO: Sporothrix brasiliensis outbreaks and the rapid emergence of feline sporotrichosis. Mycoses 2015; 58: 652–658.
25.
Pluss JL, Opal SM: Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986; 65: 143–153.
26.
Aung AK, Teh BM, McGrath C, Thompson PJ: Pulmonary sporotrichosis: case series and systematic analysis of literature on clinico-radiological patterns and management outcomes. Med Mycol 2013; 51: 534–544.
27.
Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T: Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006; 19: 95–110.
28.
Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, Lam PS, Kozal MJ, Shikuma CM, Day JN, Farrar J: Epidemiology, seasonality, and predictors of outcome of aids-associated Penicillium marneffei infection in Ho Chi Minh City, Vietnam. Clin Infect Dis 2011; 52: 945–952.
29.
Chan JF, Chan TS, Gill H, Lam FY, Trendell-Smith NJ, Sridhar S, Tse H, Lau SK, Hung IF, Yuen KY, Woo PC: Disseminated infections with Talaromyces marneffei in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis 2015; 21: 1101–1106.
30.
Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Praparattanapan J, Nelson KE: Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997; 24: 1080–1086.
31.
Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T: Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344: 110–113.
32.
Kawila R, Chaiwarith R, Supparatpinyo K: Clinical and laboratory characteristics of Penicilliosis marneffei among patients with and without HIV infection in northern Thailand: a retrospective study. BMC Infect Dis 2013; 13: 464.
33.
Duong TA: Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23: 125–130.
34.
Azar MM, Hage CA: Laboratory diagnostics for histoplasmosis. J Clin Microbiol 2017; 55: 1612–1620.
35.
Bialek R, Ernst F, Dietz K, Najvar LK, Knobloch J, Graybill JR, Schaumburg-Lever G: Comparison of staining methods and a nested PCR assay to detect Histoplasma capsulatum in tissue sections. Am J Clin Pathol 2002; 117: 597–603.
36.
Weydert JA, Van Natta TL, DeYoung BR: Comparison of fungal culture versus surgical pathology examination in the detection of histoplasma in surgically excised pulmonary granulomas. Arch Pathol Lab Med 2007; 131: 780–783.
37.
Theel ES, Jespersen DJ, Harring J, Mandrekar J, Binnicker MJ: Evaluation of an enzyme immunoassay for detection of Histoplasma capsulatum antigen from urine specimens. J Clin Microbiol 2013; 51: 3555–3559.
38.
Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, Hammoud K, Alapat D, Babady NE, Parker M, Fuller D, Noor A, Davis TE, Rodgers M, Connolly PA, El Haddad B, Wheat LJ: A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53: 448–454.
39.
Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N: 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 2016; 63:e112–e146.
40.
Kuberski T, Herrig J, Pappagianis D: False-positive IGM serology in coccidioidomycosis. J Clin Microbiol 2010; 48: 2047–2049.
41.
Vidal MS, Del Negro GM, Vicentini AP, Svidzinski TI, Mendes-Giannini MJ, Almeida AM, Martinez R, de Camargo ZP, Taborda CP, Benard G: Serological diagnosis of paracoccidioidomycosis: high rate of inter-laboratorial variability among medical mycology reference centers. PLoS Negl Trop Dis 2014; 8:e3174.
42.
Saccente M, Woods GL: Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010; 23: 367–381.
43.
Davies SF, Sarosi GA: Serodiagnosis of histoplasmosis and blastomycosis. Am Rev Respir Dis 1987; 136: 254–255.
44.
Durkin M, Witt J, LeMonte A, Wheat B, Connolly P: Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004; 42: 4873–4875.
45.
Barros MB, de Almeida Paes R, Schubach AO: Sporothrix schenckii and sporotrichosis. Clin Microbiol Rev 2011; 24: 633–654.
46.
Supparatpinyo K, Chiewchanvit S, Hirunsri P, Uthammachai C, Nelson KE, Sirisanthana T: Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14: 871–874.
47.
Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, Watkins P, Srinoulprasert Y: Antigen detection assay for identification of Penicillium marneffei infection. J Clin Microbiol 2003; 41: 432–434.
48.
Wang YF, Cai JP, Wang YD, Dong H, Hao W, Jiang LX, Long J, Chan C, Woo PC, Lau SK, Yuen KY, Che XY: Immunoassays based on Penicillium marneffei Mp1p derived from Pichia pastoris expression system for diagnosis of penicilliosis. PLoS One 2011; 6:e28796.
49.
Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA; Infectious Diseases Society of America: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807–825.
50.
Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA; Infectious Diseases Society of America: Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 1801–1812.
51.
Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC: Neglected endemic mycoses. Lancet Infect Dis 2017; 17:e367–e377.
52.
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, Tam VV, Thanh NT, Thuy TP, Hang NT, Long HB, Nhan HT, Wertheim HFL, Merson L, Shikuma C, Day JN, Chau NVV, Farrar J, Thwaites G, Wolbers M; IVAP Investigators: A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med 2017; 376: 2329–2340.
53.
Ranjana KH, Priyokumar K, Singh TJ, Gupta Ch C, Sharmila L, Singh PN, Chakrabarti A: Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45: 268–271.
54.
Kauffman CA: Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20: 115–132.
55.
Salzer HJ, Wassilew N, Kohler N, Olaru ID, Gunther G, Herzmann C, Kalsdorf B, Sanchez-Carballo P, Terhalle E, Rolling T, Lange C, Heyckendorf J: Personalized medicine for chronic respiratory infectious diseases: tuberculosis, nontuberculous mycobacterial pulmonary diseases, and chronic pulmonary aspergillosis. Respiration 2016; 92: 199–214.
56.
Dvorak Z: Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol Lett 2011; 202: 129–132.
57.
Salzer HJ, Heyckendorf J, Kalsdorf B, Rolling T, Lange C: Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines. Mycoses 2017; 60: 136–142.
58.
Restrepo A, Tobon A, Clark B, Graham DR, Corcoran G, Bradsher RW, Goldman M, Pankey G, Moore T, Negroni R, Graybill JR: Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54: 319–327.
59.
Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, Arnold S, Lentnek A, Wheat LJ: Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53: 1648–1651.
60.
Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, Cornely OA, Perfect JR: Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis 2016; 63: 356–362.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.